% | $
Quotes you view appear here for quick access.

Keryx Biopharmaceuticals Inc. Message Board

ironjinman 1 post  |  Last Activity: May 29, 2015 3:27 PM Member since: Jan 29, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • I'm curious to hear opinions on how the changes to the P3 trial design will effect the results.

    In previous trials patients were stabilized for only 3 days on 12-16 mg oral, but many used at least some rescue medication. In the current design patients were stabilized for 3 months on 8mg or less. However, no rescue medication will be allowed this trial.

    I think it will be interesting to see how it plays out. In my mind the 33%-50% reduction in required dose should counter balance for the use of rescue meds. Also, these patients were not using 3 days before starting the trial. So they should be a lot more stable. I am anticipating results in line, non inferior, with previous results.

    What are your thoughts and opinions on this topic?

    Sentiment: Strong Buy

7.98+0.23(+2.97%)Jul 31 4:00 PMEDT